GlassScriptPrepare for your visit
Rahul Sangani
Pulmonary Disease · Gainesville, GA · NPI 1598063190
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$1,168.26
in general payments reported to CMS, 2019-2025 · $760 in 2025
The $760 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Who reported paying
General payments only, top 6 by amount.
- Boehringer Ingelheim Pharmaceuticals, INC. $318.73
- Glaxosmithkline, LLC. $296.68
- Baxter Healthcare $83.03
- Genzyme Corporation $72.32
- Takeda Pharmaceuticals U.S.A., INC. $70.72
- Astrazeneca Pharmaceuticals LP $62.70
Drugs and devices associated with these payments
Trelegy Ellipta Ofev Nucala Hillrom - Vest System Model 105 Home Care Dupixent Glassia Arexvy Arikayce Avycaz Emblaveo Tezspire Jascayd
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Rahul Sangani listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/5706012/rahul-sangani